Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Improving Quality of Life Based on Electronic Patient Reported Outcomes in Patients with CLL and MDS: The Mypal Study

Blood (2024) 144 (Supplement 1): 2358.

https://doi.org/10.1182/blood-2024-204788

Published: 2024

Journal Articles

Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004

Ursula Creutzig, Martin Zimmermann, Jean-Pierre Bourquin, Michael N. Dworzak, Gudrun Fleischhack, Norbert Graf, Thomas Klingebiel, Bernhard Kremens, Thomas Lehrnbecher, Christine von Neuhoff, Jörg Ritter, Annette Sander, André Schrauder, Arend von Stackelberg, Jan Starý, Dirk Reinhardt

Blood (2013) 122 (1): 37–43.

https://doi.org/10.1182/blood-2013-02-484097

Published: 2013

Includes: Supplemental data

Journal Articles

Additional Prognostic Impact of Specific Sites of Extramedullary Leukemia in Pediatric AML with MLL-Rearrangements but Not in Core-Binding Factor (CBF) AML.

Ursula Creutzig, MD, PhD, Martin Zimmermann, PhD, Michael Dworzak, Jean-Pierre Bourquin, MD, PhD, Christine von Neuhoff, MD, Annette Sander, MD, Jan Stary, Dirk Reinhardt, MD

Blood (2012) 120 (21): 2621.

https://doi.org/10.1182/blood.V120.21.2621.2621

Published: 2012

Journal Articles

Transient and Myeloid Leukemia in Children with Down Syndrome Mosaic

Alexandra Kolenova, MD, PhD, Katarina Reinhardt, PhD, Michaela Nathrath, MD, Claudia Rossig, MD, PhD, Arend von Stackelberg, MD, Christine von Neuhoff, MD, Annette Sander, MD, Peter Svec, MD, PhD, C. Michel Zwaan, MD, PhD, Ursula Creutzig, MD, PhD, Dirk Reinhardt, MD, PhD

Blood (2011) 118 (21): 2539.

https://doi.org/10.1182/blood.V118.21.2539.2539

Published: 2011

Journal Articles

Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)

Ursula Creutzig, Martin Zimmermann, Jean-Pierre Bourquin, Michael N. Dworzak, Christine von Neuhoff, Annette Sander, André Schrauder, Andrea Teigler-Schlegel, Jan Starý, Selim Corbacioglu, Dirk Reinhardt

Blood (2011) 118 (20): 5409–5415.

https://doi.org/10.1182/blood-2011-07-364661

Published: 2011

Includes: Supplemental data

Journal Articles

Gemtuzumab Ozogamicin In Refractory Childhood Acute Myeloid Leukemia.

Dirk Reinhardt, MD, PhD, Christian M. Zwaan, MD, PhD, Annette Sander, Christine Neuhoff, Gertjan J. Kaspers, MD, PhD, Ursula Creutzig, MD

Blood (2010) 116 (21): 1075.

https://doi.org/10.1182/blood.V116.21.1075.1075

Published: 2010

Journal Articles

Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased Toxicity

Ursula Creutzig, MD, Martin Zimmermann, Michael Dworzak, Jean-Pierre Bourquin, MD, PhD, Christine Neuhoff, Annette Sander, Jan Stary, Dirk Reinhardt, MD, PhD

Blood (2010) 116 (21): 181.

https://doi.org/10.1182/blood.V116.21.181.181

Published: 2010

Journal Articles

Excellent Outcome In Infants below One Year of Age with AML – Results of Studies AML-BFM -98 and -2004

Ursula Creutzig, MD, Zimmermann Martin, Michael Dworzak, Jean-Pierre Bourquin, MD, PhD, Christine Neuhoff, Annette Sander, Jan Stary, Dirk Reinhardt, MD, PhD

Blood (2010) 116 (21): 17.

https://doi.org/10.1182/blood.V116.21.17.17

Published: 2010

Journal Articles

New Aspects for Future Stratifications In Paediatric AML: Outcome According to Cytogenetics of 386 Patients Enrolled In Study AML-BFM 2004

Christine von Neuhoff, MD, Annette Sander, MD, Jutta Bradtke, PhD, Silja Roettgers, PhD, Andrea Teigler-Schlegel, PhD, Martin Zimmermann, PhD, Johanna Ohlendorf, Nils von Neuhoff, PhD, Ursula Creutzig, MD, Dirk Reinhardt, MD, PhD

Blood (2010) 116 (21): 2741.

https://doi.org/10.1182/blood.V116.21.2741.2741

Published: 2010

Journal Articles

Is Prevention of Myeloid Leukemia Possible?.

Katarina Reinhardt, Marjolein Blink, MD, Annette Sander, Christine von Neuhoff, Katarina Boehmer, Alexandra Kolenova, Jan Stary, Denisa Mendelova, Jan-Henning Klusmann, MD, Dominik Schneider, Valerie de Haas, MD, PhD, Claudia Rossig, MD, Marry M. van den Heuvel, MD, PhD, Ursula Creutzig, MD, C. Michel Zwaan, MD, PhD, Dirk Reinhardt, MD, PhD

Blood (2009) 114 (22): 481.

https://doi.org/10.1182/blood.V114.22.481.481

Published: 2009

Journal Articles

Improvement of Survival after Relapse in Pediatric AML Over the Last Two Decades Is Related to a Standardized, Consistent and Intensive Relapse Treatment.

Annette Sander, MD, Martin Zimmermann, PhD, Dirk Reinhardt, MD, PhD, Michael Dworzak, MD, PhD, Gertjan Kaspers, MD, PhD, Ursula Creutzig, MD, PhD

Blood (2008) 112 (11): 963.

https://doi.org/10.1182/blood.V112.11.963.963

Published: 2008

Journal Articles

GATA1 Mutations in Transient Leukemia and Myeloid Leukemia in “Down” Syndrome.

Katarina Reinhardt, PhD, Katarina Boehmer, Jan-Henning Klusmann, MD, Manuela Germeshausen, PhD, Annette Sander, MD, Christine von Neuhoff, MD, Jan Stary, MD, PhD, Heribert Jürgens, MD, PhD, Arnulf Pekrun, MD, PhD, Axel Sauerbrey, MD, PhD, Charlotte M Niemeyer, MD, PhD, Gudrun Fleischhack, MD, PhD, Ursula Creutzig, MD, PhD, Dirk Reinhardt, MD, PhD

Blood (2008) 112 (11): 923.

https://doi.org/10.1182/blood.V112.11.923.923

Published: 2008

NARROW

Improving Quality of Life Based on Electronic Patient Reported Outcomes in Patients with CLL and MDS: The Mypal Study

Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004

Additional Prognostic Impact of Specific Sites of Extramedullary Leukemia in Pediatric AML with MLL-Rearrangements but Not in Core-Binding Factor (CBF) AML.

Transient and Myeloid Leukemia in Children with Down Syndrome Mosaic

Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)

Gemtuzumab Ozogamicin In Refractory Childhood Acute Myeloid Leukemia.

Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased Toxicity

Excellent Outcome In Infants below One Year of Age with AML – Results of Studies AML-BFM -98 and -2004

New Aspects for Future Stratifications In Paediatric AML: Outcome According to Cytogenetics of 386 Patients Enrolled In Study AML-BFM 2004

Is Prevention of Myeloid Leukemia Possible?.

Improvement of Survival after Relapse in Pediatric AML Over the Last Two Decades Is Related to a Standardized, Consistent and Intensive Relapse Treatment.

GATA1 Mutations in Transient Leukemia and Myeloid Leukemia in “Down” Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only